by Kanchan Madan | Nov 24, 2021 | Press Releases
KEYTRUDA is now authorized for the adjuvant treatment of sufferers with RCC at the intermediate-excessive or excessive chance of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. KEYTRUDA is the first immunotherapy...
by Kanchan Madan | Oct 27, 2021 | Press Releases
Breast cancer is the commonest cancer among ladies globally and in India. One in 4 ladies with cancer globally is diagnosed with breast cancer. Oncologists confronted with treating older ladies with breast cancer regularly ought to decide if the remedy may be more...
